Genzyme

from Wikipedia, the free encyclopedia

Genzyme Corporation

logo
legal form Corporation
founding 1981
Seat Cambridge , United StatesUnited StatesUnited States 
management Henri A. Termeer, Chairman and CEO
Number of employees 12,000 (2009)
sales $ 4.5 billion (2009)
Branch biotechnology
Website genzyme.com

Genzyme Headquarters

Sanofi Genzyme is a United States biotechnology company headquartered in Cambridge , Massachusetts . After a hostile takeover, it has been a wholly owned subsidiary of the French pharmaceutical company Sanofi since 2011 . Genzyme specializes in enzyme medication . In fiscal 2009, the company had 12,000 employees worldwide and sales of $ 4.5 billion.

history

Photo: Andreas Matern (2004)

On June 8, 1981, Genzyme was founded as a so-called start-up by Sheridan Snyder and Henry Blair. With the help of venture capital, Genzyme took over the British company Whatman Biochemicals Ltd. that same year . whose focus was on the creation of diagnostic products.

In 1982 the company acquired the British manufacturer of industrial fine chemicals and reagents Koch Light Laboratories for the product line Genzyme Fine Chemicals, which was taken over by Genzyme Pharmaceuticals just under four years later.

In 1983, Henri Termeer moved from the US pharmaceutical company Baxter International to Genzyme and took over the position of President. Two years later he was named Chief Executive Officer .

In 1986, the company was listed on the stock exchange and became a stock corporation. On April 18, 1989 Genzyme announced the merger with the US company Integrated Genetics Incorporated , founded in April 1981 .

In 2002, Genzyme acquired Pharming NV from Belgium .

In 2003 it was named "Company of the Year" in the Boston Business Journal and in 2006 as one of the "100 Best Companies to Work" in Fortune . In 2009, Genzyme was named Top Employer 2009 for the third time by Science Magazine.

On August 29, 2010, it was announced that the French pharmaceutical company Sanofi (then still operating under the name Sanofi-Aventis) wanted to take over the company for 18.5 billion US dollars. After the original takeover bid was increased from US $ 69 to US $ 74 in cash per share (equivalent to approximately US $ 20.1 billion) plus subsequent additional payments upon achievement of certain goals, Genzyme and Sanofi announced their agreement in principle on a takeover on February 15, 2011 . The takeover was completed at the beginning of the 2nd quarter of 2011.

In January 2014, Genzyme and the US pharmaceutical company Alnylam ( NASDAQ : ALNY) formed an alliance to jointly advance the development and marketing of drugs that are developed on the basis of RNA interference (RNAi or RNA silencing).

Genzyme in Germany

The US company Genzyme has been active in Germany since the early 1990s. In 2002, Genzyme Germany established itself at its current location in Neu-Isenburg near Frankfurt am Main. The company developed into a company with over 170 employees today. The focus is primarily on marketing and sales activities.

Medication

Genzyme's business units are divided into the following departments:

Genzyme's drugs include Sevelamer (trade name: Renagel / Renvela) for the treatment of dialysis patients with hyperphosphataemia . In enzyme replacement therapy , Cerezyme is used to treat Gaucher's disease and Fabrazyme is used to treat patients with Fabry's disease . Both are lysosomal storage diseases . The product Colesevelam (trade name Cholestagel) is available for the treatment of hypercholesterolemia .

Tolevamer is in the development stage for the treatment of antibiotic-associated colitis . Campath ( alemtuzumab ) is already approved for the treatment of a form of non-Hodgkin lymphoma (B-CLL), and a study is currently ongoing for its use in multiple sclerosis . For the latter, there is a collaboration with Bayer Schering Pharma .

Web links

Individual evidence

  1. a b Annual Report 2009, 10-K. (PDF) (No longer available online.) Genzyme, March 3, 2010, archived from the original on October 11, 2010 ; accessed on March 24, 2010 (English).
  2. Press release from Sanofi. (PDF; 66 kB) (No longer available online.) Archived from the original on April 21, 2015 ; Retrieved February 10, 2012 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / en.sanofi.com
  3. Information brochure for patients. (PDF; 1.4 MB) (No longer available online.) Genzyme, formerly in the original ; Retrieved March 24, 2010 .  ( Page no longer available , search in web archivesInfo: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice.@1@ 2Template: Toter Link / sanofigenzyme.de  
  4. About Genzyme. (No longer available online.) Genzyme, archived from the original on June 27, 2017 ; Retrieved March 24, 2010 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / sanofigenzyme.de
  5. ^ Genzyme Corporation: Awards and Recognition . 2009. Archived from the original on October 30, 2010. Retrieved on March 17, 2010.
  6. de.news.yahoo.com: Sanofi-Aventis offers 18.5 billion dollars for Genzyme ( Memento from September 1, 2010 in the Internet Archive )
  7. ^ Sanofi-aventis to Acquire Genzyme for $ 74.00 in Cash Per Share Plus Contingent Value Right. In: prnewswire.com. Abernathy MacGregor Group, February 16, 2011, accessed May 8, 2018 .
  8. Press release from Sanofi. (PDF; 74 kB) (No longer available online.) Archived from the original on April 20, 2015 ; Retrieved February 10, 2012 . Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / en.sanofi.com
  9. Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines ( Memento of May 16, 2017 in the Internet Archive ) PM Alnylam of January 13, 2014, accessed on April 12, 2017
  10. Genzyme in Germany: We introduce ourselves . 2008. Retrieved March 17, 2010.